Bristol Myers Squibb 2Q Revenues: $11.7 billion (+16%) 2Q Earnings: $1.1 billion (loss of $80 million 2Q20) Comments: Revlimid sales were $3.2 billion in the quarter, up 11%. Eliquis sales were $2.8 billion, up 29%. Opdivo sales were $1.9 billion, up 16%. Orencia sales were $814 million, up 9%. Pomalyst /Imnovid sales were up 15% to $854 million. Sprycel sales were $541 million, up 6%. Yervoy sales were $510 million, up 38%. Abraxane sales were down 4% to $296 million, and Empliciti sales wer...